Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
4
×
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
san francisco blog main
4
×
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
deals
eli lilly
fda
lasmiditan
migraine
startups
teva pharmaceutical
triptans
abalos therapeutics
acetonid
achillion pharmaceuticals
aglios therapeutics
What
drugs
4
×
new
4
×
drug
aims
approach
approval
arguments
bails
based
big
bio
biotech
brand
bridgebio
called
capital
car
cholesterol
class
commercialized
companies
competitors
debuts
decades
develop
developing
emerges
epigenetic
epigenetics
expensive
faces
fda
field
financial
firm
flagship’s
foe
grab
headlines
healthcare
Language
unset
Current search:
new
×
" boston blog main "
×
drugs
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments